Muneer A.  Satter net worth and biography

Muneer Satter Biography and Net Worth

Director of Annexon

Mr. Satter is the Founder and Managing Partner of Satter Medical Technology Partners, L.P., since 2016, and Chairperson of Satter Investment Management LLC, since 2012; he also manages the Satter Foundation. Prior to Satter Investment Management, Mr. Satter was a partner at Goldman Sachs where he spent 24 years in various roles, most recently as the Global Head of the Mezzanine Group in the Merchant Banking Division, where he raised and managed more than $30 billion of assets. Mr. Satter is a member, and former co-Chairperson, of the Board of Directors of Linq3 Technologies, LLC. Mr. Satter also serves as Chairman of the Boards of Directors of Aerpio Pharmaceuticals, Inc., Akebia Therapeutics, Inc., and Restorsea Holdings, LLC. He also serves as Vice Chairperson of Goldman Sachs Foundation and GS Gives, is a director of the Navy SEAL Foundation, is a director of World Business Chicago, is on the Board of Advisors of the American Enterprise Institute and is on the Board of Trustees of Northwestern University, where he is Chairperson of the Finance Committee. Mr. Satter received a BA in economics from Northwestern University, a JD from Harvard Law School and an MBA from Harvard Business School.

What is Muneer A. Satter's net worth?

The estimated net worth of Muneer A. Satter is at least $41.78 million as of November 20th, 2025. Satter owns 9,306,024 shares of Annexon stock worth more than $41,784,048 as of December 4th. This net worth estimate does not reflect any other investments that Satter may own. Learn More about Muneer A. Satter's net worth.

How do I contact Muneer A. Satter?

The corporate mailing address for Satter and other Annexon executives is , , . Annexon can also be reached via phone at 650-822-5500 and via email at [email protected]. Learn More on Muneer A. Satter's contact information.

Has Muneer A. Satter been buying or selling shares of Annexon?

Over the course of the past ninety days, Muneer A. Satter has bought $7,065,783.64 of Annexon stock. Most recently, on Friday, November 21st, Muneer A. Satter bought 422,613 shares of Annexon stock. The stock was acquired at an average cost of $4.28 per share, with a total value of $1,808,783.64. Following the completion of the transaction, the director now directly owns 9,728,637 shares of the company's stock, valued at $41,638,566.36. Learn More on Muneer A. Satter's trading history.

Who are Annexon's active insiders?

Annexon's insider roster includes Dean Artis (EVP), William Carson (Director), Jamie Dananberg (Insider), Sanjay Keswani (EVP), Jennifer Lew (CFO), Douglas Love (CEO), Michael Overdorf (EVP), Muneer Satter (Director), and Ted Yednock (EVP). Learn More on Annexon's active insiders.

Are insiders buying or selling shares of Annexon?

During the last twelve months, Annexon insiders bought shares 10 times. They purchased a total of 1,876,188 shares worth more than $7,268,165.34. During the last twelve months, insiders at the sold shares 12 times. They sold a total of 32,352 shares worth more than $93,274.67. The most recent insider tranaction occured on December, 1st when Director Jung Choi bought 33,000 shares worth more than $138,270.00. Insiders at Annexon own 11.9% of the company. Learn More about insider trades at Annexon.

Information on this page was last updated on 12/1/2025.

Muneer A. Satter Insider Trading History at Annexon

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/21/2025Buy422,613$4.28$1,808,783.649,728,637View SEC Filing Icon  
11/20/2025Buy400,000$4.48$1,792,000.009,306,024View SEC Filing Icon  
11/19/2025Buy500,000$3.94$1,970,000.008,906,024View SEC Filing Icon  
11/17/2025Buy500,000$2.99$1,495,000.007,906,024View SEC Filing Icon  
12/26/2023Buy350,000$2.88$1,008,000.007,406,024View SEC Filing Icon  
7/7/2022Buy2,453,988$3.84$9,423,313.924,408,966View SEC Filing Icon  
7/28/2020Buy200,000$17.00$3,400,000.00
See Full Table

Muneer A. Satter Buying and Selling Activity at Annexon

This chart shows Muneer A Satter's buying and selling at Annexon by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Annexon Company Overview

Annexon logo
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $4.49
Low: $4.25
High: $4.55

50 Day Range

MA: $3.38
Low: $2.68
High: $4.51

2 Week Range

Now: $4.49
Low: $1.28
High: $5.66

Volume

2,488,278 shs

Average Volume

3,148,846 shs

Market Capitalization

$537.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2